H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on NAGE stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily centered around the promising clinical results and strategic intellectual property acquisitions by Niagen Bioscience. The company has demonstrated significant advancements in the application of its patented nicotinamide riboside (NR) ingredient, Niagen, particularly in treating Werner syndrome, a rare genetic disorder. The clinical study highlighted that Niagen supplementation led to substantial improvements in cardiovascular and skin health markers, showcasing its potential therapeutic benefits.
Moreover, Niagen Bioscience has secured exclusive rights to valuable intellectual property through a commercial license agreement with Haukeland University Hospital, which positions the company uniquely in the development of treatments for Parkinson’s disease. This agreement, coupled with the ongoing NOPARK trial, underscores the potential of NR in addressing early-stage Parkinson’s disease. These strategic moves and the robust scientific data supporting NR’s applicability in rare conditions contribute to the Buy rating and a 12-month price target of $11.
In another report released on July 28, TR | OpenAI – 4o also initiated coverage with a Buy rating on the stock with a $10.50 price target.